EDRF1 Knockout HAP1 Polyclonal Cells are a polyclonal CRISPR/Cas9-edited knockout population targeting the EDRF1 gene in HAP1 cells. This product provides a heterogeneous pool of cells with gene disruption, offering a loss-of-function model for functional studies. The polyclonal format ensures a high proportion of edited cells, facilitating scalable experiments without clonal derivation.
HAP1 is a near-haploid human cell line derived from a male chronic myeloid leukemia patient, harboring the BCR-ABL1 fusion. Its adherent, fibroblast-like phenotype and single-copy genome simplify gene editing and genotype-phenotype correlations. HAP1 cells are extensively used in CRISPR knockout screens, and they express key transcriptional regulators including GATA1, enabling investigation of erythroid-related factors in a tractable system.
EDRF1 encodes a nuclear cofactor that enhances GATA1 transcriptional activity at erythroid gene promoters, including the globin loci HBB and HBA, as well as ALAS2 and SLC4A1. Additionally, EDRF1 binds to HSP70 (HSPA1A), modulating apoptosis by influencing the balance of BCL2 and BAX during erythropoiesis. Expression of EDRF1 is stimulated by erythropoietin (EPO) signaling through the EPO receptor?CJAK2?CSTAT5 pathway, placing it downstream of the master regulator GATA1 and upstream of critical erythroid maturation events.
In the HAP1 context, the EDRF1 knockout polyclonal population allows dissection of its molecular functions without confounding allelic variability. Users can perform co-immunoprecipitation to assess interactions with GATA1 or HSP70, and apoptosis assays such as Annexin V staining to evaluate cell survival. The near-haploid background ensures unambiguous loss-of-function phenotypes, making it an ideal platform for biochemical and pharmacological studies in erythropoiesis and leukemic transformation.
Applications include investigating globin gene regulation, fetal hemoglobin switching, and modeling hematological diseases like ???thalassemia, sickle cell disease, and Diamond?Blackfan anemia. The cells support drug screening for anemia or leukemia therapies and can be assayed by RT?qPCR for HBB/HBA, Western blotting for EDRF1, flow cytometry with CD71/CD235a for differentiation tracking, and RNA?seq for pathway analysis. For further information, contact Ascent Research.
